400 Technology Square
14 articles with Akero Therapeutics
Akero Therapeutics and InSphero partner to evaluate AKR-001 using InSphero's 3D InSight™ Human Liver Disease platform
3D InSight™ Human Liver Disease Platform will be used to screen effects of Akero lead program AKR-001 on underlying metabolic and fibrotic drivers of NAFLD and NASH.
Akero Therapeutics, Inc. announced that members of the management team will provide a business overview and update at the Morgan Stanley 17th Annual Global Healthcare Conference at 5:25 p.m. ET on Monday, September 9, 2019 in New York, NY.
Advanced AKR-001 into Phase 2a BALANCED clinical study in NASH
Akero Therapeutics Announces Dosing of First Patient in Phase 2a Study of AKR-001 to Treat NASH (BALANCED)
Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced the dosing of the first patient in its Phase 2a clinical study of AKR-001, a novel FGF21 analog, for the treatment of NASH (the BALANCED study).
Akero Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
The aggregate gross proceeds to Akero from the offering were approximately $105.8 million, before deducting underwriting discounts and commissions and other offering expenses.
This week marked initial public offering news from six biopharma companies. Here’s a look.
Akero Therapeutics, Inc. announced the pricing of its initial public offering of 5,750,000 shares of common stock at a public offering price of $16.00 per share.
Akero Therapeutics Initiates Phase 2a Clinical Trial of Investigational Therapy AKR-001 for the Treatment of NASH
Akero Therapeutics, Inc. announced that it has screened the first patient for its Phase 2a clinical trial evaluating AKR-001, the company's lead product candidate for the treatment of NASH.
Akero Therapeutics Appoints Life Sciences Investment Banking Veteran Bill White as Chief Financial Officer and Head of Corporate Development
Akero Therapeutics, Inc., a biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases, today announced the appointment of Bill White as CFO and Head of Corporate Development.
Akero Therapeutics, Inc. announced the appointment of Jane Pritchett Henderson to its Board of Directors.
BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.
Akero Therapeutics, Inc. announced the company will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA next week.
Akero Therapeutics Announces $70 Million in New Financing to Advance Therapeutic Pipeline for NASH, Serious Metabolic Diseases
The financing will support the advancement of Akero's lead clinical candidate AKR-001
Akero Therapeutics Inc., a biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases, today announced the appointment of Mark Iwicki, chairman and CEO of Kala Pharmaceuticals, to Akero's Board of Directors.